AAHA issues new canine diabetes guidelines for 2026
Bottom line
AAHA has released its 2026 Diabetes Management Guidelines for Dogs, its first standalone canine diabetes document after previously combining dog and cat guidance in a single resource. The update, announced September 1, 2026, gives veterinary teams step-by-step recommendations on diagnosis, insulin therapy, monitoring, dietary management, diabetic ketoacidosis, and troubleshooting, while reflecting newer tools such as continuous glucose monitors and longer-acting “peakless” insulins including degludec and glargine U-300. AAHA says the split from feline guidance is meant to better reflect the species-specific nature of canine diabetes, where dogs are considered absolutely insulin-deficient and require insulin therapy. (aaha.org)
Why it matters: For primary care teams, the practical shift is less about a new disease concept than a new workflow. The guidelines put more emphasis on clinical control, avoiding hypoglycemia, and using blood glucose curves or CGM data rather than spot checks to guide dose changes. They also outline where newer basal insulins may support once-daily dosing in some dogs, and they include algorithms for insulin adjustment, hypoglycemia, and workups for difficult-to-regulate cases, including concurrent disease and insulin resistance. That could help practices standardize follow-up, improve pet parent communication, and reduce some of the friction that makes long-term diabetic management hard to sustain. (aaha.org)
What to watch: Expect closer attention to how widely general practices adopt CGMs, once-daily basal insulin protocols, and AAHA’s new client-education and discharge tools over the next year. (aaha.org)
Key facts
- Organization
- American Animal Hospital Association (AAHA)
- Document
- 2026 Diabetes Management Guidelines for Dogs
- Release date
- September 1, 2026
- First standalone canine document
- Yes; AAHA previously combined dog and cat diabetes guidance
- Canine diabetes
- Absolute insulin deficiency caused by permanent beta cell loss
- Monitoring tools
- Continuous glucose monitors, blood glucose curves, and veterinary-calibrated portable blood glucose monitors
- Insulin options
- Degludec and glargine U-300
- Supporters
- Adapet Medical, Boehringer Ingelheim, Dechra, and Merck Animal Health
AAHA has published new 2026 Diabetes Management Guidelines for Dogs, giving veterinary teams a canine-specific roadmap for diagnosing, treating, and monitoring diabetes mellitus at a moment when both monitoring technology and insulin choices are changing. The release, announced September 1, 2026, marks the first time AAHA has separated its diabetes guidance into distinct canine and feline documents, a notable structural change for a disease area that has traditionally been covered together. (aaha.org)
That split reflects a larger clinical point: AAHA says canine diabetes should be approached on its own terms. In dogs, diabetes is characterized by absolute insulin deficiency caused by permanent beta cell loss, and insulin therapy remains the foundation of treatment. The new document builds on AAHA’s earlier combined diabetes guidance, but updates it around species-specific pathophysiology, monitoring, and treatment decisions that are more relevant to general practice in 2026. (aaha.org)
The headline changes center on monitoring and insulin selection. AAHA highlights the growing use of more affordable continuous glucose monitors, alongside longer-acting basal insulins such as degludec and glargine U-300, which may allow once-daily dosing in some dogs. In its insulin treatment section, AAHA says degludec may be considered a first-choice option and cites evidence that about 84% of dogs in one recent study were maintained on once-daily administration. The monitoring guidance also stresses that the goal is not tight blood glucose control, but maximizing time below the renal threshold for glucosuria while avoiding hypoglycemia. Spot checks are described as unreliable, and low CGM readings ideally should be confirmed with a veterinary-calibrated portable blood glucose monitor when the patient is not showing clinical signs. (aaha.org)
AAHA has also packaged the guidance as a practical toolkit for clinics. Beyond the core recommendations on diagnosis, insulin therapy, dietary management, and diabetic ketoacidosis, the guideline hub includes algorithms for insulin adjustment, glucose-curve interpretation, discharge instructions, and client-facing education materials. In the troubleshooting section, AAHA urges clinicians to look hard for concurrent disease in poorly regulated dogs, calling out obesity, dental disease, infection, hypercortisolism, pancreatitis, renal disease, and reproductive status among the contributors to insulin resistance. It also advises delaying some endocrine testing until diabetes treatment has been underway long enough to reduce false positives. (aaha.org)
Outside AAHA, early trade coverage has focused on the same two themes: CGMs and long-acting insulin. dvm360 quoted task force member Audrey K. Cook saying care for “doggy diabetics” has changed dramatically in recent years because of inexpensive CGMs and a better understanding of how to use long-acting insulins. AAHA Chief Medical Officer Jessica Vogelsang, in the association’s release, said the organization was “especially excited” to separate canine and feline guidance for the first time because of the disease’s distinct behavior in each species. (dvm360.com)
Why it matters: For veterinary professionals, this looks like a guideline update with operational consequences. It gives general practices more formal backing to use CGM-supported titration, to prioritize clinical signs and weight stability over chasing perfect glucose numbers, and to consider whether some dogs may benefit from once-daily basal insulin strategies. Just as important, it reinforces that unregulated diabetes often isn’t simply a dosing problem. The guidance pushes teams toward a fuller workup for insulin resistance and toward better pet parent counseling about follow-up, expectations, and the long-term commitment required. That combination could improve adherence, reduce preventable hypoglycemia, and make diabetic case management more sustainable in primary care. (aaha.org)
There’s also an industry angle worth noting. AAHA says the guidelines were supported by Adapet Medical, Boehringer Ingelheim, Dechra, and Merck Animal Health, underscoring how closely diabetes management sits at the intersection of clinical standards, device adoption, and pharmaceutical strategy. That doesn’t diminish the guideline’s utility, but it does mean practices may see increased education, marketing, and product positioning around CGMs, insulin selection, and diabetic care pathways in the months ahead. (aaha.org)
What to watch: The next question is how quickly these recommendations move from guideline language into everyday workflows. Over the next 6 to 12 months, watch for broader uptake of CGMs in general practice, more discussion of once-daily basal insulin protocols for selected dogs, and follow-on education from AAHA and industry around discharge tools, monitoring algorithms, and pet parent support. (aaha.org)